美国急性淋巴细胞白血病1980-2017年基于SEER数据库的人群结局研究
总体5年生存率从1990年前的51%提升至2010年后的72%,各年龄组成人及儿童均有改善,但60岁以上患者仍低于30%。非洲裔、西班牙裔及低收入家庭与较差生存相关。
要点
- ALL总体5年生存率从1990年前的51%升至2010年后的72%。
- 儿童和青少年5年生存率分别从73%和55%升至93%和74%。
- 60岁以上患者5年生存率仍低于30%,非洲裔、西班牙裔及低收入者生存较差。
核心结论
- 美国ALL患者结局在各年龄组持续改善,但老年患者及弱势人群仍存在差距。
主要发现
- 总体5年生存率从1990年前的51%提高至2010年后的72%。
- 儿童(0-14岁)5年生存率从73%升至93%,青少年(15-19岁)从55%升至74%。
- 20-29岁、30-39岁、40-59岁成人5年生存率分别从33%升至59%、24%升至59%、14%升至43%。
- 60岁以上患者5年生存率仍低于30%。
- 2010年后Ph阴性ALL的5年生存率为73%,Ph阳性ALL为50%。
临床怎么用
- 应关注老年ALL患者及非洲裔、西班牙裔、低收入人群的生存差异并优化支持治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment in acute lymphoblastic Leukemia (ALL) has evolved and improved dramatically over the past four decades. We assessed the outcome of ALL overall, and the two major subsets of Philadelphia chromosome (Ph)-positive and Ph-negative ALL by age, time periods, ethnicity, median household income, and geographic county area. A total of 12 788 patients diagnosed with ALL from 1980 to 2017 were included. We performed an analysis to better evaluate the outcome evolution in ALL according to time period and patient's demographic factors. The overall 5-year survival rates have improved significantly over time, from 51% before 1990 to 72% since 2010. The survival rates for children (age 0 to 14 years) and adolescents (age 15 to 19 years) have improved from 73% and 55% before 1990 to 93% and 74% since 2010, respectively. Similarly, the rates had improved from 33% to 59% for adults 20 to 29 years old, 24% to 59% for 30 to 39 years old, and 14% to 43% for 40 to 59 years old between the two time periods. The rates remained under 30% in older patients (60+ years). Since 2010, patients with Ph-negative ALL had 5-year survival rate of 73% and those with Ph-positive ALL 50%. African Americans, Hispanic ethnicity, and lower household income were associated with inferior survival. The outcome of patients with ALL showed continued improvement across all age groups in the US. The recent introduction of targeted therapies, together with optimized supportive care, will continue to improve outcomes, particularly in older patients.
引用
- Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021. PMID: 33709456. doi:10.1002/ajh.26156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。